International
The Pandemic Supercharged Decentralized Trials, Now What?
For Andy Coravos the tipping point was the Biogen Conference in Boston, February 2020. While only about 100 people attended the meeting, it became one…
Share this:
For Andy Coravos the tipping point was the Biogen Conference in Boston, February 2020. While only about 100 people attended the meeting, it became one of the most notorious super spreader events of the COVID-19 pandemic, ultimately leading to an estimated hundreds of thousands of cases around the world (Science, Dec. 2020).
“From that point on it was all hands on deck,” says Coravos, CEO of HumanFirst, a San Francisco-based firm that helps pharma companies and hospitals evaluate, select, and use sensors for clinical trials or home care. “Suddenly, it wasn’t safe for people, even the sickest patients, to go to a clinic or hospital site.” Thousands of trials ground to a halt.
One of the keys to restarting those trials was incorporating digital measures. There were lots of tools available already, but the question was often “Is this tool properly validated – and for this condition? Is it cyber secure?” Coravos says. That’s exactly what her team does. So they jumped into action.
The issues were not just which devices worked best for the job, but what exactly should be measured. “Think about sleep,” Coravos says. “What exactly is sleep? Should you measure how long you stayed asleep? How often you sweated? How you felt in the morning? Could you lift your grandkids up the next day?” In many ways, this was a whole different world from the traditional trial process of giving patients drugs and then checking their vitals and labwork.
Coravos was not alone is mobilizing her team for a full-throttle shift to decentralized clinical trials (DCTs). For anyone in the clinical trial field, no matter how peripherally, the onset of the COVID-19 pandemic was dramatic.
Rosamund Round of contract research firm Paraxel called the company’s president as soon as she heard about the pandemic’s surge in China. Vice President of the company’s Patient Innovation Center, Round advised that Paraxel start pressing customers to switch to DCTs. “The majority of clients were onboard immediately,” she says. “We had some who said ‘We’re not worried, this will blow over in a couple of weeks,’ but they came along too soon enough.”
She adds that, “I cannot think of a time that innovation has moved so quickly. These last two years have been wild.”
While it was a trial by fire, the crisis was tempered by the fact that so many people had already been working on encouraging the adoption of DCTs. The tools, framework, and mindset for the shift was there, it was just a matter of putting it in action and bringing regulators along. What experts on the frontlines have learned from this experience is straightforward: It’s crucial to validate the tools, some of DCTs tools and methods are now here to stay, and flexibility is mandatory, because not all patients want to do DCTs.
“The embrace of decentralized clinical trials during the COVID-19 pandemic worked tremendously well,” says John Cassidy, Global Head, eClinical Product & Commercial at Labcorp Drug Development.
Dos and Don’ts
At first, the pandemic uncovered the low-hanging fruit – things that were being done inefficiently, just because they were always done that way.
“There is no reason a patient needs to come into a clinic for gait analysis,” says Craig Lipset, co-chair of the Decentralized Trials Research Alliance (DTRA). “Especially if that’s going to be a hardship for them. Why not use a remote device? They will literally do more walking to get from the parking lot than they do in the clinic.”
This puts digital health technologies (DHTs) in a pivotal position. “People have access to more DHTs now, from fitness trackers to apps and they have become more accustomed to tracking health metrics and continuous monitoring,” says Yashoda Sharma, program director of the Digital Medicine Society (DiMe). But some patients prefer to visit a clinical site. Either they don’t want the intrusion of a home visit, or they may just like the experience of visiting with staff.
Digital Medicine Society
“We had one rheumatoid arthritis trial where we were planning for DCT,” says Round “But the patients said they actually preferred clinic visits.” Meanwhile, parents of kids with rare diseases or other conditions, and people with low level chronic diseases far preferred DCTs. The lesson, Round says, is “Don’t make assumptions. Ask patients. Ask them a lot of things, and ask them often.”
Teonna Woolford, CEO of Sickle Cell Reproductive Health, says she found the daily e-diary she had to keep more time-consuming than a visit to a clinic would have been, during the trial she was participating in as the pandemic unfolded. “Maybe it’s because I’m a CEO, so I’m very busy,” she says. “But it seemed like a trip to a clinic once in a while would have been less bother.” Woolford adds that time off work, gas, parking, etc. “adds up” and she understands that for some patients a DCT is probably the only way they can participate in a trial.
Sickle Cell Reproductive Health Education Directive
Another critical factor was the regulatory environment. While that has typically been a tough landscape to navigate, the pandemic prompted some agencies to fall in step. The FDA quickly issued a guidance, (FDA’s Guidance for Clinical Trial Conduct During the COVID-19 Pandemic).
But just as importantly, the FDA aligned with the European Medicines Agency (EMA) to make it easier to meet both agencies requirements. “For many years the FDA had their rules and the EMA had theirs. But during the pandemic they created a framework so we could meet both agency’s requirements without jeopardizing quality or safety,” says Rasmus Hogreffe, VP of DCT Innovation at Medable.
Oracle Health Sciences
Oracle stepped up to help accelerate the evaluation of the COVID-19 vaccines, some of the most rapidly tested and evaluated products in history. The data giant was well positioned to help with this effort. “We are the best at this,” says Katherine Vandebelt, Global Head of Clinical Innovation for Oracle Health Sciences. “Data collection, data architecture, analytics. That put us in position to lead in remote monitoring, consent, and more.”
One project Oracle developed, v-safe, helped monitor reported side effects from COVID-19 vaccines via patients’ smartphone or computer. It is an app that allows a confidential health check-in, as well as surveys and other tools. The company reports that over a hundred million records are in the system.
That data has already proved very valuable. As early as June of 2021, a New England Journal of Medicine report documented, that: “Early data from the v-safe surveillance system, the v-safe pregnancy registry, and the VAERS do not indicate any obvious safety signals with respect to pregnancy or neonatal outcomes associated with Covid-19 vaccination in the third trimester of pregnancy.”
Finally, there is the pressing issue of logistics. Simply delivering medications to patients became a challenge during the pandemic. Companies such as Medable, Paraxel, and others are now touting their ability to deliver temperature-controlled drugs within tight time windows to ensure that patients receive their medications safely and in a timely manner.
What’s Next for DCTs
“Training and adoption for sites is an area that deserves additional focus and is necessary to the success of DCTs,” says Labcorp’s Cassidy. He points out that decreasing the burden and training curve of using DCT methodologies can broaden the reach of those trials and progress the industry towards broader flexibility in trial conduct.
Lipset was involved in the first all-remote trial under an investigational new drug (IND) application, which was carried out by Pfizer about a decade ago (Orri et al., Contemp Clin Trials, 2014). This was a randomized, placebo-controlled, Phase IV (REMOTE) trial to evaluate tolterodine extended release (ER) 4 mg for overactive bladder.
“Some things worked and some didn’t. We were open about both,” he says. But there was not much momentum for DCTs even after that trial. Lipset points out that the two “guardrails” of clinical trials are patient safety and data integrity. It’s not surprising, he says, that people in this industry are cautious.
While he admits there was a surge of DCT adoption during the pandemic, he says it is premature to fly the “mission accomplished” banner. “It is conceivable that such a conservative industry will slip back into its comfort zone,” he says.
But he also points to the facts that FDA and other regulators (e.g in Sweden and Denmark) seem DCT friendly now, many sponsors have made “sizeable” commitments to this approach, and there is lots of guidance on how to pursue it (See Sidebar: Playbooks, Guidances, and Endpoints).
Vandebelt sees a new push for more real word data (RWD). All this data from remote monitoring provides an opportunity for data aggregators such as Oracle she says. “What happened over the last two years was unprecedented, and it took a lot of money and energy.” Now there can be a focus on using that data in new ways.
In keeping with that, Hogreffe anticipates a push toward “bring your own device.” As devices are standardized, which platform patients have for personal use will become less relevant. Digital sensors will be plug and play. Meanwhile, the number of people with access to internet is steadily increasing, reaching a record 5 billion this year.
Says DiMe’s Sharma, “Many of the challenges facing clinical trials in general, still exist. The two biggest are trust and access.” Sharma points out that many patients have little trust in the healthcare system now. “Without a support system of clinicians and study teams, patients may lose even more confidence in the system and become reluctant to participate.”
Another question is whether DCTs can address the nagging issue of diversity, including ethnic and LGBQT participation. Making trials more convenient for people with cellphones or adding home visits doesn’t naturally tend to increase diversity. Many companies and organizations, including DiMe and Paraxel, are now looking at this since it has become clear that diversity is a major issue in data integrity for clinical trials.
Besides the urgency of safety during the pandemic, there is data supporting DCTS. A recent study from Tufts Center for the Study of Drug Development found that, on average, decentralized trials achieved a net financial benefit ranging from 5 to 14 times for Phase II and III trials through reduced trial timelines and other factors.
Working through issues like e-consent, logistics, and security have helped the pioneers of DCTs not only weather the pandemic, but thrive because of it. Participating in a clinical trial should be as smooth as buying on Amazon,” says Medable’s Hogreffe. “One click and you are in.”
He adds that taking about 12 years to bring a drug to market “Is unambitious. People want to invest their time in something more productive.”
Round had a personal view of the crisis as she had COVID-19 herself and ended up taken by “blue lights,” as she says, to a hospital where she was seriously ill. “That was the last place I wanted to be.”
She notes that while she’s always been passionate about patient care, that experience helped her realize what a huge advantage DCTs are for some people. “Patients really appreciate it. DCT is not going away,” she says.
| The FDA was quick to release guidances (see below) on how to conduct trials during COVID-19. Proponents of DCTs responded with comments, playbooks, and other documents that helped guide sponsors and others through this unfamiliar terrain.
Below are some of them: DiMe’s Library of Digital Endpoints: DiMe’s comment in response to the FDA draft guidance on: DiMe’s Playbook: Digital Clinical Measures |
| FDA’s draft guidance on Digital Health Technologies for Remote Data Acquisition in Clinical Investigations |
| Oracle and Informa’s survey on Clinical Trial Management in a Post-Pandemic World |
| Paraxel’s Discussions on Diversity Report |
Malorye Branca is a freelenace science writer based in Acton, MA.
The post The Pandemic Supercharged Decentralized Trials, Now What? appeared first on Inside Precision Medicine.
fda clinical trials pandemic covid-19 european sweden china
International
Red Candle In The Wind
Red Candle In The Wind
By Benjamin PIcton of Rabobank
February non-farm payrolls superficially exceeded market expectations on Friday by…
Share this:
By Benjamin PIcton of Rabobank
February non-farm payrolls superficially exceeded market expectations on Friday by printing at 275,000 against a consensus call of 200,000. We say superficially, because the downward revisions to prior months totalled 167,000 for December and January, taking the total change in employed persons well below the implied forecast, and helping the unemployment rate to pop two-ticks to 3.9%. The U6 underemployment rate also rose from 7.2% to 7.3%, while average hourly earnings growth fell to 0.2% m-o-m and average weekly hours worked languished at 34.3, equalling pre-pandemic lows.
Undeterred by the devil in the detail, the algos sprang into action once exchanges opened. Market darling NVIDIA hit a new intraday high of $974 before (presumably) the humans took over and sold the stock down more than 10% to close at $875.28. If our suspicions are correct that it was the AIs buying before the humans started selling (no doubt triggering trailing stops on the way down), the irony is not lost on us.
The 1-day chart for NVIDIA now makes for interesting viewing, because the red candle posted on Friday presents quite a strong bearish engulfing signal. Volume traded on the day was almost double the 15-day simple moving average, and similar price action is observable on the 1-day charts for both Intel and AMD. Regular readers will be aware that we have expressed incredulity in the past about the durability the AI thematic melt-up, so it will be interesting to see whether Friday’s sell off is just a profit-taking blip, or a genuine trend reversal.
AI equities aside, this week ought to be important for markets because the BTFP program expires today. That means that the Fed will no longer be loaning cash to the banking system in exchange for collateral pledged at-par. The KBW Regional Banking index has so far taken this in its stride and is trading 30% above the lows established during the mini banking crisis of this time last year, but the Fed’s liquidity facility was effectively an exercise in can-kicking that makes regional banks a sector of the market worth paying attention to in the weeks ahead. Even here in Sydney, regulators are warning of external risks posed to the banking sector from scheduled refinancing of commercial real estate loans following sharp falls in valuations.
Markets are sending signals in other sectors, too. Gold closed at a new record-high of $2178/oz on Friday after trading above $2200/oz briefly. Gold has been going ballistic since the Friday before last, posting gains even on days where 2-year Treasury yields have risen. Gold bugs are buying as real yields fall from the October highs and inflation breakevens creep higher. This is particularly interesting as gold ETFs have been recording net outflows; suggesting that price gains aren’t being driven by a retail pile-in. Are gold buyers now betting on a stagflationary outcome where the Fed cuts without inflation being anchored at the 2% target? The price action around the US CPI release tomorrow ought to be illuminating.
Leaving the day-to-day movements to one side, we are also seeing further signs of structural change at the macro level. The UK budget last week included a provision for the creation of a British ISA. That is, an Individual Savings Account that provides tax breaks to savers who invest their money in the stock of British companies. This follows moves last year to encourage pension funds to head up the risk curve by allocating 5% of their capital to unlisted investments.
As a Hail Mary option for a government cruising toward an electoral drubbing it’s a curious choice, but it’s worth highlighting as cash-strapped governments increasingly see private savings pools as a funding solution for their spending priorities.
Of course, the UK is not alone in making creeping moves towards financial repression. In contrast to announcements today of increased trade liberalisation, Australian Treasurer Jim Chalmers has in the recent past flagged his interest in tapping private pension savings to fund state spending priorities, including defence, public housing and renewable energy projects. Both the UK and Australia appear intent on finding ways to open up the lungs of their economies, but government wants more say in directing private capital flows for state goals.
So, how far is the blurring of the lines between free markets and state planning likely to go? Given the immense and varied budgetary (and security) pressures that governments are facing, could we see a re-up of WWII-era Victory bonds, where private investors are encouraged to do their patriotic duty by directly financing government at negative real rates?
That would really light a fire under the gold market.
Government
Trump “Clearly Hasn’t Learned From His COVID-Era Mistakes”, RFK Jr. Says
Trump "Clearly Hasn’t Learned From His COVID-Era Mistakes", RFK Jr. Says
Authored by Jeff Louderback via The Epoch Times (emphasis ours),
President…
Share this:
Authored by Jeff Louderback via The Epoch Times (emphasis ours),
President Joe Biden claimed that COVID vaccines are now helping cancer patients during his State of the Union address on March 7, but it was a response on Truth Social from former President Donald Trump that drew the ire of independent presidential candidate Robert F. Kennedy Jr.
During the address, President Biden said: “The pandemic no longer controls our lives. The vaccines that saved us from COVID are now being used to help beat cancer, turning setback into comeback. That’s what America does.”
President Trump wrote: “The Pandemic no longer controls our lives. The VACCINES that saved us from COVID are now being used to help beat cancer—turning setback into comeback. YOU’RE WELCOME JOE. NINE-MONTH APPROVAL TIME VS. 12 YEARS THAT IT WOULD HAVE TAKEN YOU.”
An outspoken critic of President Trump’s COVID response, and the Operation Warp Speed program that escalated the availability of COVID vaccines, Mr. Kennedy said on X, formerly known as Twitter, that “Donald Trump clearly hasn’t learned from his COVID-era mistakes.”
“He fails to recognize how ineffective his warp speed vaccine is as the ninth shot is being recommended to seniors. Even more troubling is the documented harm being caused by the shot to so many innocent children and adults who are suffering myocarditis, pericarditis, and brain inflammation,” Mr. Kennedy remarked.
“This has been confirmed by a CDC-funded study of 99 million people. Instead of bragging about its speedy approval, we should be honestly and transparently debating the abundant evidence that this vaccine may have caused more harm than good.
“I look forward to debating both Trump and Biden on Sept. 16 in San Marcos, Texas.”
Mr. Kennedy announced in April 2023 that he would challenge President Biden for the 2024 Democratic Party presidential nomination before declaring his run as an independent last October, claiming that the Democrat National Committee was “rigging the primary.”
Since the early stages of his campaign, Mr. Kennedy has generated more support than pundits expected from conservatives, moderates, and independents resulting in speculation that he could take votes away from President Trump.
Many Republicans continue to seek a reckoning over the government-imposed pandemic lockdowns and vaccine mandates.
President Trump’s defense of Operation Warp Speed, the program he rolled out in May 2020 to spur the development and distribution of COVID-19 vaccines amid the pandemic, remains a sticking point for some of his supporters.
Operation Warp Speed featured a partnership between the government, the military, and the private sector, with the government paying for millions of vaccine doses to be produced.
President Trump released a statement in March 2021 saying: “I hope everyone remembers when they’re getting the COVID-19 Vaccine, that if I wasn’t President, you wouldn’t be getting that beautiful ‘shot’ for 5 years, at best, and probably wouldn’t be getting it at all. I hope everyone remembers!”
President Trump said about the COVID-19 vaccine in an interview on Fox News in March 2021: “It works incredibly well. Ninety-five percent, maybe even more than that. I would recommend it, and I would recommend it to a lot of people that don’t want to get it and a lot of those people voted for me, frankly.
“But again, we have our freedoms and we have to live by that and I agree with that also. But it’s a great vaccine, it’s a safe vaccine, and it’s something that works.”
On many occasions, President Trump has said that he is not in favor of vaccine mandates.
An environmental attorney, Mr. Kennedy founded Children’s Health Defense, a nonprofit that aims to end childhood health epidemics by promoting vaccine safeguards, among other initiatives.
Last year, Mr. Kennedy told podcaster Joe Rogan that ivermectin was suppressed by the FDA so that the COVID-19 vaccines could be granted emergency use authorization.
He has criticized Big Pharma, vaccine safety, and government mandates for years.
Since launching his presidential campaign, Mr. Kennedy has made his stances on the COVID-19 vaccines, and vaccines in general, a frequent talking point.
“I would argue that the science is very clear right now that they [vaccines] caused a lot more problems than they averted,” Mr. Kennedy said on Piers Morgan Uncensored last April.
“And if you look at the countries that did not vaccinate, they had the lowest death rates, they had the lowest COVID and infection rates.”
Additional data show a “direct correlation” between excess deaths and high vaccination rates in developed countries, he said.
President Trump and Mr. Kennedy have similar views on topics like protecting the U.S.-Mexico border and ending the Russia-Ukraine war.
COVID-19 is the topic where Mr. Kennedy and President Trump seem to differ the most.
Former President Donald Trump intended to “drain the swamp” when he took office in 2017, but he was “intimidated by bureaucrats” at federal agencies and did not accomplish that objective, Mr. Kennedy said on Feb. 5.
Speaking at a voter rally in Tucson, where he collected signatures to get on the Arizona ballot, the independent presidential candidate said President Trump was “earnest” when he vowed to “drain the swamp,” but it was “business as usual” during his term.
John Bolton, who President Trump appointed as a national security adviser, is “the template for a swamp creature,” Mr. Kennedy said.
Scott Gottlieb, who President Trump named to run the FDA, “was Pfizer’s business partner” and eventually returned to Pfizer, Mr. Kennedy said.
Mr. Kennedy said that President Trump had more lobbyists running federal agencies than any president in U.S. history.
“You can’t reform them when you’ve got the swamp creatures running them, and I’m not going to do that. I’m going to do something different,” Mr. Kennedy said.
During the COVID-19 pandemic, President Trump “did not ask the questions that he should have,” he believes.
President Trump “knew that lockdowns were wrong” and then “agreed to lockdowns,” Mr. Kennedy said.
He also “knew that hydroxychloroquine worked, he said it,” Mr. Kennedy explained, adding that he was eventually “rolled over” by Dr. Anthony Fauci and his advisers.
MaryJo Perry, a longtime advocate for vaccine choice and a Trump supporter, thinks votes will be at a premium come Election Day, particularly because the independent and third-party field is becoming more competitive.
Ms. Perry, president of Mississippi Parents for Vaccine Rights, believes advocates for medical freedom could determine who is ultimately president.
She believes that Mr. Kennedy is “pulling votes from Trump” because of the former president’s stance on the vaccines.
“People care about medical freedom. It’s an important issue here in Mississippi, and across the country,” Ms. Perry told The Epoch Times.
“Trump should admit he was wrong about Operation Warp Speed and that COVID vaccines have been dangerous. That would make a difference among people he has offended.”
President Trump won’t lose enough votes to Mr. Kennedy about Operation Warp Speed and COVID vaccines to have a significant impact on the election, Ohio Republican strategist Wes Farno told The Epoch Times.
President Trump won in Ohio by eight percentage points in both 2016 and 2020. The Ohio Republican Party endorsed President Trump for the nomination in 2024.
“The positives of a Trump presidency far outweigh the negatives,” Mr. Farno said. “People are more concerned about their wallet and the economy.
“They are asking themselves if they were better off during President Trump’s term compared to since President Biden took office. The answer to that question is obvious because many Americans are struggling to afford groceries, gas, mortgages, and rent payments.
“America needs President Trump.”
Multiple national polls back Mr. Farno’s view.
As of March 6, the RealClearPolitics average of polls indicates that President Trump has 41.8 percent support in a five-way race that includes President Biden (38.4 percent), Mr. Kennedy (12.7 percent), independent Cornel West (2.6 percent), and Green Party nominee Jill Stein (1.7 percent).
A Pew Research Center study conducted among 10,133 U.S. adults from Feb. 7 to Feb. 11 showed that Democrats and Democrat-leaning independents (42 percent) are more likely than Republicans and GOP-leaning independents (15 percent) to say they have received an updated COVID vaccine.
The poll also reported that just 28 percent of adults say they have received the updated COVID inoculation.
The peer-reviewed multinational study of more than 99 million vaccinated people that Mr. Kennedy referenced in his X post on March 7 was published in the Vaccine journal on Feb. 12.
It aimed to evaluate the risk of 13 adverse events of special interest (AESI) following COVID-19 vaccination. The AESIs spanned three categories—neurological, hematologic (blood), and cardiovascular.
The study reviewed data collected from more than 99 million vaccinated people from eight nations—Argentina, Australia, Canada, Denmark, Finland, France, New Zealand, and Scotland—looking at risks up to 42 days after getting the shots.
Three vaccines—Pfizer and Moderna’s mRNA vaccines as well as AstraZeneca’s viral vector jab—were examined in the study.
Researchers found higher-than-expected cases that they deemed met the threshold to be potential safety signals for multiple AESIs, including for Guillain-Barre syndrome (GBS), cerebral venous sinus thrombosis (CVST), myocarditis, and pericarditis.
A safety signal refers to information that could suggest a potential risk or harm that may be associated with a medical product.
The study identified higher incidences of neurological, cardiovascular, and blood disorder complications than what the researchers expected.
President Trump’s role in Operation Warp Speed, and his continued praise of the COVID vaccine, remains a concern for some voters, including those who still support him.
Krista Cobb is a 40-year-old mother in western Ohio. She voted for President Trump in 2020 and said she would cast her vote for him this November, but she was stunned when she saw his response to President Biden about the COVID-19 vaccine during the State of the Union address.
“I love President Trump and support his policies, but at this point, he has to know they [advisers and health officials] lied about the shot,” Ms. Cobb told The Epoch Times.
“If he continues to promote it, especially after all of the hearings they’ve had about it in Congress, the side effects, and cover-ups on Capitol Hill, at what point does he become the same as the people who have lied?” Ms. Cobb added.
“I think he should distance himself from talk about Operation Warp Speed and even admit that he was wrong—that the vaccines have not had the impact he was told they would have. If he did that, people would respect him even more.”
International
There will soon be one million seats on this popular Amtrak route
“More people are taking the train than ever before,” says Amtrak’s Executive Vice President.
Share this:
While the size of the United States makes it hard for it to compete with the inter-city train access available in places like Japan and many European countries, Amtrak trains are a very popular transportation option in certain pockets of the country — so much so that the country’s national railway company is expanding its Northeast Corridor by more than one million seats.
Related: This is what it's like to take a 19-hour train from New York to Chicago
Running from Boston all the way south to Washington, D.C., the route is one of the most popular as it passes through the most densely populated part of the country and serves as a commuter train for those who need to go between East Coast cities such as New York and Philadelphia for business.
Veronika Bondarenko
Amtrak launches new routes, promises travelers ‘additional travel options’
Earlier this month, Amtrak announced that it was adding four additional Northeastern routes to its schedule — two more routes between New York’s Penn Station and Union Station in Washington, D.C. on the weekend, a new early-morning weekday route between New York and Philadelphia’s William H. Gray III 30th Street Station and a weekend route between Philadelphia and Boston’s South Station.
More Travel:
- A new travel term is taking over the internet (and reaching airlines and hotels)
- The 10 best airline stocks to buy now
- Airlines see a new kind of traveler at the front of the plane
According to Amtrak, these additions will increase Northeast Corridor’s service by 20% on the weekdays and 10% on the weekends for a total of one million additional seats when counted by how many will ride the corridor over the year.
“More people are taking the train than ever before and we’re proud to offer our customers additional travel options when they ride with us on the Northeast Regional,” Amtrak Executive Vice President and Chief Commercial Officer Eliot Hamlisch said in a statement on the new routes. “The Northeast Regional gets you where you want to go comfortably, conveniently and sustainably as you breeze past traffic on I-95 for a more enjoyable travel experience.”
Here are some of the other Amtrak changes you can expect to see
Amtrak also said that, in the 2023 financial year, the Northeast Corridor had nearly 9.2 million riders — 8% more than it had pre-pandemic and a 29% increase from 2022. The higher demand, particularly during both off-peak hours and the time when many business travelers use to get to work, is pushing Amtrak to invest into this corridor in particular.
To reach more customers, Amtrak has also made several changes to both its routes and pricing system. In the fall of 2023, it introduced a type of new “Night Owl Fare” — if traveling during very late or very early hours, one can go between cities like New York and Philadelphia or Philadelphia and Washington. D.C. for $5 to $15.
As travel on the same routes during peak hours can reach as much as $300, this was a deliberate move to reach those who have the flexibility of time and might have otherwise preferred more affordable methods of transportation such as the bus. After seeing strong uptake, Amtrak added this type of fare to more Boston routes.
The largest distances, such as the ones between Boston and New York or New York and Washington, are available at the lowest rate for $20.
stocks pandemic japan european
‘I couldn’t stand the pain’: the Turkish holiday resort that’s become an emergency dental centre for Britons who can’t get treated at home
Beloved mall retailer files Chapter 7 bankruptcy, will liquidate
Is the National Guard a solution to school violence?
Red Candle In The Wind
Rand Paul Teases Senate GOP Leader Run – Musk Says “I Would Support”
Trump “Clearly Hasn’t Learned From His COVID-Era Mistakes”, RFK Jr. Says
The next pandemic? It’s already here for Earth’s wildlife
There will soon be one million seats on this popular Amtrak route
Chinese migration to US is nothing new – but the reasons for recent surge at Southern border are
The Grinch Who Stole Freedom
-
Uncategorized3 weeks agoAll Of The Elements Are In Place For An Economic Crisis Of Staggering Proportions
-
Uncategorized3 weeks agoCalifornia Counties Could Be Forced To Pay $300 Million To Cover COVID-Era Program
-
International4 days agoEyePoint poaches medical chief from Apellis; Sandoz CFO, longtime BioNTech exec to retire
-
Uncategorized2 weeks agoApparel Retailer Express Moving Toward Bankruptcy
-
Uncategorized4 weeks agoIndustrial Production Decreased 0.1% in January
-
International3 days agoWalmart launches clever answer to Target’s new membership program
-
Uncategorized3 weeks agoRFK Jr: The Wuhan Cover-Up & The Rise Of The Biowarfare-Industrial Complex
-
Uncategorized3 weeks agoGOP Efforts To Shore Up Election Security In Swing States Face Challenges